Zejula Tablet, Film Coated
Product Images NDC 0173-0909

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zejula (NDC 0173-0909). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecular Structure (Zejula Tab Spl Graphic 01)

FDA Label Image

Figure 1. Progression-free Survival In Patients With Hr-deficient Tumors (intent-to-treat Population, N = 373) (Zejula Tab Spl Graphic 02)

FDA Label Image

Figure 2. Progression-free Surivival In The Overall Population (intent-to-treat Population, N=733) (Zejula Tab Spl Graphic 03)

FDA Label Image

Figure 3. Progression-free Survival In The Gbrcamut Cohort Based On Irc Assessment (intent-to-treat Population, N = 203) (Zejula Tab Spl Graphic 04)

FDA Label Image

Zejula 100 mg Tablet 30 Count Label (Zejula Tab Spl Graphic 05)

FDA Label Image

Zejula 200 mg Tablet 30 Count Label (Zejula Tab Spl Graphic 06)

FDA Label Image

Zejula 300 mg Tablet 30 Count Label (Zejula Tab Spl Graphic 07)